GB-0895 / Generate Biomedicines - LARVOL DELTA

A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD (clinicaltrials.gov) - P1 | N=156 | Active, not recruiting | Sponsor: Generate Biomedicines | Recruiting ➔ Active, not recruiting

Enrollment closed • First-in-human • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Late Breaking Abstract - GB-0895, a high-affinity anti-TSLP mAb, demonstrates prolonged half-life and sustained pharmacological activity supporting every 6-month dosing in asthma (ERS 2025) - "A single dose of GB-0895 drives PD biomarker suppression for at least 6 months, reflecting the broad anti-inflammatory effects of the anti-TSLP mechanism seen with tezepelumab. These results support dosing GB-0895 every 6-months for the treatment of severe asthma."

Late-breaking abstract • Asthma • Immunology • Respiratory Diseases • IL13 • IL5

A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD (clinicaltrials.gov) - P1 | N=156 | Recruiting | Sponsor: Generate Biomedicines

New P1 trial • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

A long-acting high affinity anti-TSLP antibody (GB-0895) for severe asthma identified leveraging a proprietary machine learning platform (ERS 2024) - "The approved anti-TSLP antibody (tezepelumab) requires monthly administration; a longer duration treatment could improve adherence and outcomes. Conclusions GB-0895 has the potential for best-in-class dosing for patients with severe asthma. A phase 1 dose escalation trial in asthma patients is underway."

Machine learning • Asthma • Immunology • Inflammation • Respiratory Diseases